よむ、つかう、まなぶ。
04資料2-1_森野委員提出資料（おたふくかぜワクチンファクトシート第２版） (52 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202403/20240325_J.pdf (accessed
2026/04/24).
150.
Nakayama T, Kawamura A, Sogawa Y, et al. Phase III, open-label, single-arm study of a new
MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine
dose in healthy Japanese children aged 5-6 years. J Infect Chemother 2024.
151.
Habib MA, Povey M, Casabona G, Singh T, Abu-Elyazeed R. Clinical trials show similar safety
outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR)
vaccines. Hum Vaccin Immunother 2023; 19(1): 2188852.
152.
Soriolo N, Benoni R, Dalla Valle D, et al. Adverse events following Measles-Mumps-Rubella
and varicella immunization: A safety profile analysis and comparison of different vaccination schedules
based on the Italian Pharmacovigilance Network in the Veneto Region. Prev Med Rep 2024; 41:
102711.
153.
Geier DA, Geier MR. A longitudinal cohort study of childhood MMR vaccination and seizure
disorder among American children. Brain Dev 2021; 43(2): 251–67.
154.
Gavrielov-Yusim N, Hoshen M, Singer SR, Neumann L, Balicer RD. The weight of MMRV-
related febrile convulsions among other clinical factors contributing to febrile convulsions in children.
Vaccine 2014; 32(39): 4954–9.
155.
Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps,
rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR Recomm Rep 2010; 59(Rr-3): 1–12.
156.
Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine
and the risk of febrile seizures. Pediatrics 2010; 126(1): e1–8.
52
2026/04/24).
150.
Nakayama T, Kawamura A, Sogawa Y, et al. Phase III, open-label, single-arm study of a new
MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine
dose in healthy Japanese children aged 5-6 years. J Infect Chemother 2024.
151.
Habib MA, Povey M, Casabona G, Singh T, Abu-Elyazeed R. Clinical trials show similar safety
outcomes including febrile convulsion rates for GSK's and Merck's measles-mumps-rubella (MMR)
vaccines. Hum Vaccin Immunother 2023; 19(1): 2188852.
152.
Soriolo N, Benoni R, Dalla Valle D, et al. Adverse events following Measles-Mumps-Rubella
and varicella immunization: A safety profile analysis and comparison of different vaccination schedules
based on the Italian Pharmacovigilance Network in the Veneto Region. Prev Med Rep 2024; 41:
102711.
153.
Geier DA, Geier MR. A longitudinal cohort study of childhood MMR vaccination and seizure
disorder among American children. Brain Dev 2021; 43(2): 251–67.
154.
Gavrielov-Yusim N, Hoshen M, Singer SR, Neumann L, Balicer RD. The weight of MMRV-
related febrile convulsions among other clinical factors contributing to febrile convulsions in children.
Vaccine 2014; 32(39): 4954–9.
155.
Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps,
rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR Recomm Rep 2010; 59(Rr-3): 1–12.
156.
Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine
and the risk of febrile seizures. Pediatrics 2010; 126(1): e1–8.
52